Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Platinum-Sensitive Ovarian Cancer
NCT07684612Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- May 2030
- Countries
- 4
01
Overview
A Phase 3 trial of mocertatug rezetecan in ovarian cancer, sponsored by GSK. Started Sep 2026; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07684612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684612.